Starting immediately, Sativex – a cannabis based medicinal spray – is available in Italy as a prescription medication to treat multiple sclerosis spasticity, a symptom that effects 3 in 4 individuals with multiple sclerosis. Unlike medications such as Marinol, which is made from synthetic THC and legal in the U.S., Sativex is made from actual cannabis derivative, and contains CBD as well as THC. Sativex becoming available this month in Italy comes two months after health authorities in the state approved it as a medicine, the 21st country to do so; Canada was the first in 2005.
“The launch of Sativex in Italy is a key milestone in the commercialization of this important new medicine,” stated Justin Gover, CEO of GW Pharmaceuticals, the company behind the spray.
Although unfortunately multiple sclerosis spascity is the only condition in which the spray has been approved for, the number of conditions are likely to grow in the near future
There are currently 9 other countries in which Sativex is pending as an officially accepted medicine.